



CLAIMS:


1. A therapeutic or diagnostic composition, comprising an excipient or pharmaceutical additive and a compound having the following formula:




wherein R_1 is selected from the group consisting of




wherein R₂ is selected from the group consisting of



Methylenediphosphonate,



Difluoromethylenediphosphonate, and



Monofluoromethylenediphosphonate,

and wherein Cat⁺ represents one or more organic or mineral cations, comprising the proton, identical or different, in

the same compound, excepting 3-methyl-3-butene-1-yl-difluoromethylenediphosphonate, and 3-methyl-3-butene-1-yl-methylenediphosphonate.

2. The composition according to claim 1, wherein said excipient or pharmaceutical additive is a vaccine adjuvant.

3. The composition according to claim 1, wherein said composition can be safely administered to a primate.

4 A method for selectively inhibiting Ty9δ2 lymphocytes, comprising:

contacting said Ty9δ2 lymphocytes with an effective amount of the composition according to claim 1.

5. A method for treating a patient that suffer from a pathology that activates Ty9δ2 lymphocytes, comprising:

administering to said patient in need thereof an effective amount of the composition according to claim 1.

6. A method for treating a pathology leading to an activation of Ty9δ2 lymphocytes in a primate, comprising:

administering to said primate in need thereof an effective amount of the composition according to claim 1.

7. A method for treating parasitosis in a primate, comprising:

administering to said primate in need thereof an effective amount of the composition according to claim 1.

8. The method according to claim 6, wherein said parasitosis is selected from the group consisting of malaria, visceral leishmaniosis, toxoplasmosis.

9. A method for treating an autoimmune malady in a primate, comprising:

administering to said primate in need thereof an effective amount of the composition according to claim 1.

10. The method according to claim 8, wherein said malady is behcet malady.

11. A method for selectively inhibiting T γ 9 δ 2 lymphocytes in an extracorporeal medium, comprising:

contacting said T γ 9 δ 2 lymphocytes in said extracorporeal medium with an effective amount of the composition according to claim 1.

12. A method for inhibiting polyclonal proliferation of Ty982 lymphocytes, comprising:

contacting said Ty982 lymphocytes with an effective amount of the composition according to claim 1.